Navigation Links
Monsanto's Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment
Date:3/10/2009

e product performance, regulatory approvals, business and financial plans and other non-historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: continued competition in seeds, traits and agricultural chemicals; the company's exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public acceptance of biotechnology products; the success of the company's research and development activities; the outcomes of major lawsuits; developments related to foreign currencies and economies; successful operation of recent acquisitions; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company's estimates related to distribution inventory levels; the company's ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters and accidents on the agriculture business or the company's facilities; and other risks and factors detailed in the company's most recent periodic report to the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this release. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results.

    Contact       Media:        Danielle Stuart (314-694-2478)
                  Investors:    Scarlett Lee Foster (314-694-8148)


'/>"/>
SOURCE Monsanto Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NanoLogix Inc. Announces Historical First in Energy Generation With Bioreactor-Produced Hydrogen at Welchs
2. Historic Breakthrough in Fighting Childrens Batten Disease as China Stem Cells Give New Lease on Life to 6 Year Old California Boy
3. A Communitys Fight to Preserve its Historical and Rural Culture in Virginia: Biotechnology CEO Gets Involved
4. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
5. Campus Celebrates Historic Milestone
6. Growing Interest in DNA-Based Genetic Testing Among African American with Historic Election of President Elect Barack Obama
7. African Ancestry, Educators, Identity Experts Launch DNA Education Project during Historic Black History Month; 7th Graders Score High on Ultimate Self Test
8. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
9. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
10. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
11. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... 2015 This year has been one ... US Patented Pearl’s Premium Ultra Low Maintenance Lawn ... country that are coming out of record bad weather. ... of major global concerns related to water, health, and ... the alternative to the standard, water-wasting, chemical-treated standard lawn. ...
(Date:5/20/2015)... -- Health eCareers, the healthcare industry,s online career hub, ... looking for the flexibility of short-term assignments through ... tool dedicated exclusively to temporary and shift work ... employers to quickly find and hire experienced professionals ... other temporary positions, eliminating the time and resources ...
(Date:5/20/2015)... DIEGO , May 20, 2015  Cypher ... announced a collaboration with Celgene Corporation to apply ... genomic biomarkers that associate with patient response to ... is intended to help accelerate patient access to ... efficiencies in clinical research and development and potentially ...
(Date:5/20/2015)... Mulhouse, France, Cambridge, MA (PRWEB) May 20, 2015 ... of high quality transporter assay services for Drug-Drug ... Pharmacology, and Rhenovia Pharma, a world leader in ... using Translational Quantitative Systems Pharmacology supported by biosimulation, ... agreement. , The agreement allows both companies to ...
Breaking Biology Technology:Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
... for Bevasiranib Broadly Covers siRNA Targeting of, VEGF Expression, Further Strengthening ... ... MIAMI, March 18 OPKO Health, Inc. (Amex: OPK ),today announced ... and Trademark Office (USPTO) for methods related to the use and,administration of ...
... safety, effectiveness, and environmental impact of removing pollutant, ... ... products-, BOURNE, Mass., ... company has closed the first,tranche of a $2.5 million institutional financing ...
... Mich., March 18 Neogen Corporation,(Nasdaq: NEOG ) announces the following ... When: March 25, 2008 11:00 EDT, Where: ... Simply log on to the web at the address ... of Neogen Corporation, +1-800-234-5333. If you are unable to participate during ...
Cached Biology Technology:OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 2OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 3OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 4Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 2Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 3Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 4
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:5/20/2015)... OXFORD, Conn. , May 20, 2015 ... "Company") announces that its wholly owned subsidiary, 3D-ID LLC, ... contractor under Team Battelle for the biometrics technology portion ... Unrestricted Suite Contract from the Department of the Army. ... facial recognition products developed for government, law enforcement and ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... from a mutation in one genome are complicated enough, ... genomes: the DNA in the nucleus and in the ... genomic disconnects cause disease. In a step in that ... traced one such incompatibility in fruit flies down to ...
... ten million, with dogs producing approximately 1,000 tonnes of excrement ... as a major source of the parasite egg, Toxocara ... humans. The aim of the study, led by Dr ... of Veterinary Sciences and published in the international scientific journal, ...
... Here,s another reason why you should include olive oil ... the Journal of Leukocyte Biology ... significantly reduces intestinal ischemia (restricted blood supply) and the ... returns). The compound, called "oleuropein aglycone," is the most ...
Cached Biology News:Mitochondrial mutations: When the cell's 2 genomes collide 2Mitochondrial mutations: When the cell's 2 genomes collide 3Caring for dogs to reduce spread of parasite eggs harmful to humans 2Olive oil component alleviates intestinal ischemia and reperfusion 2
... Adapted to Sf-900 II ... isolated from Spodoptera frugiperda ... cells (1). The Sf21 ... serum-free suspension culture in ...
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
MAGP-2 (C-19)...
... Immunogen: Synthetic peptide derived from ... junctophilin-2. Specificity: Specific for the ... controls: mouse skeletal muscle homogenates frozen ... Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: Store at ...
Biology Products: